Clinical features of and effects of angiotensin system antagonists on amiodarone-induced pulmonary toxicity

International Journal of Cardiology

Volumn 140, Issue 3, 2010, Pages 328-335

  Nikaido, Akira ^a   Tada, Takeshi ^a   Nakamura, Kazufumi ^a   Murakami, Masato ^a   Banba, Kimikazu ^a   Nishii, Nobuhiro ^a   Fuke, Soichiro ^a   Nagase, Satoshi ^a   Sakuragi, Satoru ^a   Morita, Hiroshi ^a   Ohe, Tohru ^a   Kusano, Kengo Fukushima ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Amiodarone; Angiotensin; Antiarrhythmia agents; Apoptosis; Heart failure

Indexed keywords

AMIODARONE; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANGIOTENSIN II; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; CANDESARTAN HEXETIL; CARBON MONOXIDE; CARVEDILOL; ENALAPRIL MALEATE; GLYCOPROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMIDAPRIL; KREBS VON DEN LUNGEN 6 PROTEIN; LOSARTAN POTASSIUM; MONOCYTE CHEMOTACTIC PROTEIN 1; OLMESARTAN; QUINAPRIL; TELMISARTAN; TEMOCAPRIL; TRANSFORMING GROWTH FACTOR BETA1; UNCLASSIFIED DRUG; VALSARTAN; ANTIARRHYTHMIC AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; APOPTOSIS; ARTICLE; CELL PROTECTION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DEFIBRILLATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEART ARRHYTHMIA; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG ALVEOLUS EPITHELIUM; LUNG DIFFUSION; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK ASSESSMENT; ADOLESCENT; BLOOD; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DRUG EFFECT; HEART FAILURE; LUNG ALVEOLUS; LUNG ALVEOLUS CELL; MIDDLE AGED; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICAL MODEL; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIODARONE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTI-ARRHYTHMIA AGENTS; APOPTOSIS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HEART FAILURE; HUMANS; LOGISTIC MODELS; LUNG DISEASES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PNEUMOCYTES; PULMONARY ALVEOLI; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 77953561520     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2008.11.106     Document Type: Article

References (26)

1. Heger JJ, Prystowsky EN, Jackman WM, et al. Clinical efficacy and electrophysiology during long-term therapy for recurrent ventricular tachycardia or ventricular fibrillation. N Engl J Med 1981;305:539-45.
2. Heger JJ, Prystowsky EN, Zipes DP. Clinical efficacy of amiodarone in treatment of recurrent ventricular tachycardia and ventricular fibrillation. Am Heart J 1983;106:887-94.
3. Wellens HJ, Brugada P, Abdollah H. Effect of amiodarone in paroxysmal supraventricular tachycardia with or without Wolff-Parkinson-White syndrome. Am Heart J 1983;106:876-80.
4. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart failure: meta-analysis of individual data from 6500 patients in randomised trials. Amiodarone Trials Meta-Analysis Investigators. Lancet 1997;350:1417-24.
5. Burkart F, Pfisterer M, Kiowski W, Follath F, Burckhardt D. Effect of antiarrhythmic therapy on mortality in survivors of myocardial infarction with asymptomatic complex ventricular arrhythmias: Basel Antiarrhythmic Study of Infarct Survival (BASIS). J Am Coll Cardiol 1990;16:1711-8.
6. Kodama I, Kamiya K, Toyama J. Cellular electropharmacology of amiodarone. Cardiovasc Res 1997;35:13-29.
7. Kodama I, Kamiya K, Toyama J. Amiodarone: ionic and cellular mechanisms of action of the most promising class III agent. Am J Cardiol 1999;84:20R-8R.
8. Rotmensch HH, Liron M, Tupilski M, Laniado S. Possible association of pneumonitis with amiodarone therapy. Am Heart J 1980;100:412-3.
9. Marchlinski FE, Gansler TS, Waxman HL, Josephson ME. Amiodarone pulmonary toxicity. Ann Intern Med 1982;97:839-45.
10. Magro SA, Lawrence EC, Wheeler SH, Krafchek J, Lin HT,Wyndham CR. Amiodarone pulmonary toxicity: prospective evaluation of serial pulmonary function tests. J Am Coll Cardiol 1988;12:781-8.
11. Li X, Rayford H, Uhal BD. Essential roles for angiotensin receptor AT1a in bleomycin-induced apoptosis and lung fibrosis in mice. Am J Pathol 2003;163:2523-30.
12. Li X, Zhang H, Soledad-Conrad V, Zhuang J, Uhal BD. Bleomycininduced apoptosis of alveolar epithelial cells requires angiotensin synthesis de novo. Am J Physiol 2003;284:501-7.
13. Chen YC, Lu SN, Lin MC. Interstitial pneumonitis after combination therapy with pegylated interferon alpha-2b and ribavirin for chronic hepatitis C. Chang Gung Med J 2007;30:92-7.
14. Teramoto S, Yamamoto H, Ouchi Y. Clinical efficacy and toxicity of gefitinib in patients with lung cancer. Lancet 2003;361:1992-3.
15. Wang R, Zagariya A, Ibarra-Sunga O, et al. Angiotensin II induces apoptosis in human and rat alveolar epithelial cells. Am J Physiol 1999;276:885-9.
16. KawanoH,DoYS,KawanoY, et al.Angiotensin II hasmultiple profibrotic effects in human cardiac fibroblasts. Circulation 2000;101:1130-7.
17. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990;82:51-9.
18. Roughton FJ, Forster RE. Relative importance of diffusion and chemical reaction rates in determining rate of exchange of gases in the human lung, with special reference to true diffusing capacity of pulmonary membrane and volume of blood in the lung capillaries. J Appl Physiol 1957;11:290-302.
19. Endoh Y, Hanai R, Uto K, et al. Diagnostic accuracy of KL-6 as a marker of amiodarone-induced pulmonary toxicity. Pacing Clin Electrophysiol 2000;23:2010-3.
20. Held C, Gerstein HC, Yusuf S, et al. Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk. Circulation 2007;115:1371-5.
21. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomised trial of low-dose amiodarone in severe congestive heart failure. Grupo de Estudio de la Sobrevida en la Insuficiencia Cardiaca en Argentina (GESICA). Lancet 1994;344:493-8.
22. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. Survival Trial of Antiarrhythmic Therapy in Congestive Heart Failure. N Engl J Med 1995;333:77-82.
23. Bargout R, Jankov A, Dincer E, et al. Amiodarone induces apoptosis of human and rat alveolar epithelial cells in vitro. Am J Physiol 2000;278: 1039-44.
24. Uhal BD, Wang R, Laukka J, Zhuang J, Soledad-Conrad V, Filippatos G. Inhibition of amiodarone-induced lung fibrosis but not alveolitis by angiotensin system antagonists. Pharm Toxicol 2003;92:81-7.
25. Otsuka M, Takahashi H, Shiratori M, Chiba H, Abe S. Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist. Thorax 2004;59:31-8.
26. Coats AJ. Ethical authorship and publishing. Int J Cardiol 2009;131: 149-50.